The advisors on Nuclidium’s funding round
Swiss clinical-stage radiopharmaceutical company Nuclidium completed a Series B financing round, raising CHF 79 million (EUR 84 million).
Vischer advised Nuclidium throughout the operation, while Walder Wyss advised Angelini Ventures, Kurma Partners and Wellington Partners, in connection with their role co-lead investors.
Headquartered in Basel, Nuclidium is a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform.
The round
The round saw Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group) serving as lead investors, with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK and HighLight Capital, as well as existing investors.
The Vischer team
The Vischer team lineup featured Matthias Staehelin (pictured above), Pauline Pfirter, Lucas Sturzenegger, Stefanie Havalda and Kelly Chevrolet (all corporate/M&A), as well as Nadia Tarolli (tax).
The Walder Wyss team
The team Walder Wyss lineup working on the matter included partner Alexander Gutmans (corporate/M&A and venture capital, pictured), managing associates Karina Tschon (corporate/M&A and venture capital) and Celine Weber (life Sciences and health care), as well as associates Christoph Burckhardt (corporate/M&A and venture capital), Oerjan Wickart (corporate/M&A and venture capital), Bojan Momic (employment) and Frederik Weber (employment).
